Immunotherapy given before or after surgery is increasingly used across several cancer areas. In an article published in the Journal of Internal Medicine, researchers at Karolinska Institutet present ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

Combined epigenetic and immune checkpoint therapy altered the tumour microenvironment in platinum-resistant ovarian cancer.

Concomitant medications are emerging as a modifiable prognostic factor for immune checkpoint inhibitor treatment outcomes. This Review by Stone et al. highlights the potential immunomodulatory ...

Phase 3 trial data show datopotamab deruxtecan reduces the risk of disease progression or death in patients with metastatic TNBC.

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

But an association with improved overall survival failed to reach statistical significance ...

A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of ...

Please provide your email address to receive an email when new articles are posted on . Cancer therapy may reduce cardiorespiratory fitness, as measured by peak VO 2, for years after treatment.

Health systems spending $4 billion on cancer care are expanding capacity and decentralizing access to improve oncology services nationwide.